2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement 
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif.,...
Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021
Seizure Related Benefits noted by caregivers included reduction in frequency, fewer triggers causing seizures, and shorter recovery time when seizure...
Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a...
Aleafia Health to Announce 2021 First Quarter Results
TORONTO, April 16, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) will...
Immutep Receives A$1,155,055 R&D Tax Incentive
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased...
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions Ublituximab was generally well tolerated, with...
Robert J. Folkes Joins PetVivo Holdings, Inc. as Chief Financial Officer
PETVIVO HOLDINGS, INC Robert J. Folkes MINNEAPOLIS, MN, US, April 16, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV)...
New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
New findings from MS PATHS show that treatment with TYSABRI® (natalizumab) can lead to meaningful improvements in mental and social health compared...
CareDx to Present at UNOS Transplant Management Forum
Company to showcase its latest integrated solutions for improving care across the whole transplant journeySOUTH SAN FRANCISCO, Calif., April 16,...
Tauriga Sciences Inc. Showcases Blister Pack Design for its Evergreen Mint Flavor, Delta 8 THC Infused, Version of Tauri-Gum
Tauriga 04-16-2021 Image of Delta 8 THC Infused Tauri-Gum™ Blister Pack NEW YORK, NY, April 16, 2021 (GLOBE NEWSWIRE) --...
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI
Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies...
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their...
Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital...
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL
Nicox Investor & Media Contact: Gavin Spencercommunications@nicox.com+33 (0)4 97 24 53 00 Mary-Ann Chang mchang@lifesciadvisors.com +44 7483 284 853Nicox Media...
New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb...
Biomea Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused...
Akoya Biosciences Announces Pricing of Initial Public Offering
MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
SeaSpine Prices Public Offering of Common Stock
CARLSBAD, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE) (“SeaSpine” or the “Company”), a global medical...
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the...
Revive Reschedules Annual and Special Meeting and Provides Dial-In Information
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty...